Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
Homologous recombination (HR) related gene alterations are present in a significant subset of prostate, breast, ovarian, pancreatic, lung and colon cancers rendering these tumors as potential responders to specific DNA damaging agents. A small molecule acylfulvene prodrug, LP-184, metabolizes to an active compound by the oxidoreductase activity of enzyme Prostaglandin Reductase 1 (PTGR1), which is frequently elevated in multiple solid tumor types. Prior work demonstrated that cancer cell lines deficient in a spectrum of (DNA damage repair) DDR pathway genes show increased susceptibility to LP-184...
April 17, 2024: Cancer Res Commun
Iain R Timmins, Frank Dudbridge
Population differences in risk of disease are common, but the potential genetic basis for these differences is not well understood. A standard approach is to compare genetic risk across populations by testing for mean differences in polygenic scores, but existing studies that use this approach do not account for statistical noise in effect estimates (i.e., the GWAS betas) that arise due to the finite sample size of GWAS training data. Here, we show using Bayesian polygenic score methods that the level of uncertainty in estimates of genetic risk differences across populations is highly dependent on the GWAS training sample size, the polygenicity (number of causal variants), and genetic distance (FST) between the populations considered...
April 2024: PLoS Genetics
Katsumasa Nakamura, Keiji Nihei, Yoshihiro Saito, Naoto Shikama, Shin-Ei Noda, Ryusuke Hara, Toshiyuki Imagumbai, Takashi Mizowaki, Takeshi Akiba, Etsuo Kunieda, Masanori Someya, Saiji Ohga, Jiro Kawamori, Takuyo Kozuka, Yosuke Ota, Koji Inaba, Takeshi Kodaira, Yoshiyuki Itoh, Kouta Funakoshi, Yoshikazu Kagami
BACKGROUND: The aim of this multi-institutional phase II study was to confirm the safety and the potential efficacy of moderately hypofractionated intensity-modulated radiotherapy (IMRT) with prostate-based image-guidance for Japanese patients. METHODS: Patients with low- or intermediate-risk localized prostate cancer were eligible. Patients with a part of high risk (having only one of the following factors, cT3a, 20 < PSA ≤ 30, or GS = 8 or 9) were also included...
April 17, 2024: International Journal of Clinical Oncology
Ahad Amer Alsaiari, Amal F Gharib, Maha Mahfouz Bakhuraysah, Amani A Alrehaili, Shatha M Algethami, Hayfa Ali Alsaif, Norah Al Harthi, Mohammed Ageeli Hakami
Among the most prevalent forms of cancer are breast, lung, colon-rectum, and prostate cancers, and breast cancer is a major global health challenge, contributing to 2.26 million cases with approximately 685,000 deaths worldwide in 2020 alone, typically beginning in the milk ducts or lobules that produce and transport milk during lactation and it is becoming challenging to treat as the tissues are developing resistance, which makes urgent calls for new multitargeted drugs. The multitargeted drug design provides a better solution, simultaneously targeting multiple pathways, even when the drug resists one, it remains effective for others...
April 17, 2024: Medical Oncology
Lufeng Zheng, Yuxin Zhang, Shuang Mei, Tianyuan Xie, Yunting Zou, Yuting Wang, Han Jing, Shengtao Xu, Pierre Dramou, Zhen Xu, Jindong Li, Yang Zhou, Miao-Miao Niu
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Here, we discovered dual SOS1/EGFR-targeting compounds via pharmacophore-based docking screening. The most prominent compound SE-9 exhibited nanomolar inhibition activity against both SOS1 and EGFR and efficiently suppressed the phosphorylation of ERK and AKT in prostate cancer cells PC-3...
April 17, 2024: Journal of Medicinal Chemistry
Justine M Dupere, Eric E Brost, Matthew E Hainy, Christine U Lee, Matthew W Urban, Bradley J Stish, Christopher L Deufel
BACKGROUND: High dose rate brachytherapy is commonly used in the treatment of prostate cancer. Treatment planning is often performed under transrectal ultrasound (US) guidance, but brachytherapy needles can be challenging to digitize due to the presence of poor US conspicuity and imaging artifacts. The plan accuracy and quality, however, are dependent on the proper visualization of the needles with millimeter accuracy. PURPOSE: This work describes a technique for generating a color overlay of needle locations atop the grayscale US image...
April 17, 2024: Medical Physics
Zhivka Dancheva, Sophiya Chausheva, Tanya Stoeva, Marina Dyankova, Tsvetelina Yordanova, Borislav Chaushev, Rostislav Marinov, Viktor Nikolov, Pavel Abushev, Georgi Todorov, Eleonora Dimitrova, Aneliya Klisarova, Deyan Anakievski
OBJECTIVE: Recently, gallium-68-prostate-specific membrane antigen-11 (68 Ga-PSMA-11) positron emission tomography/computed tomography (PET/CT) has become a key imaging method in prostate carcinoma staging and biochemical progression, with varying sensitivities in different studies (from 40% to 80%). After four years of experience with 68 Ga-PSMA-11 PET/CT, we found that it is possible to detect lesions with increased PSMA expression in patients with undetectable prostate specific antigen (PSA) levels after radical prostatectomy...
April 18, 2024: Hellenic Journal of Nuclear Medicine
Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
The introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) like nivolumab, ipilimumab, pembrolizumab, and atezolizumab play a pivotal role by disturbing signaling pathways that limit the immune system's ability to fight tumor cells. Despite the profound impact of these treatments, not all tumors are responsive. Recent research efforts have been focused on understanding how cancer cells manage to evade the immune response and identifying the possible mechanisms behind resistance to immunotherapy...
December 31, 2024: Cancer Biology & Therapy
Fengnian Zhao, Jinge Zhao, Xinyuan Wei, Yifu Shi, Nanwei Xu, Sha Zhu, Junru Chen, Guangxi Sun, Jindong Dai, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Xu Hu, Haoyang Liu, Junjie Zhao, Zhenhua Liu, Ling Nie, Pengfei Shen, Ni Chen, Hao Zeng
BACKGROUND: KI67 is a well-known biomarker reflecting cell proliferation. We aim to elucidate the predictive role of KI67 in the efficacy of abiraterone for patients with advanced prostate cancer (PCa). METHODS: Clinicopathological data of 152 men with metastatic PCa, who received abiraterone therapy were retrospectively collected. The KI67 positivity was examined by immunohistochemistry using the prostate biopsy specimen. The predictive value of KI67 on the therapeutic efficacy of abiraterone was explored using Kaplan-Meier curve and Cox regression analysis...
April 17, 2024: Prostate
Breanna B Greteman, Natalie J Del Vecchio, Crystal J Garcia-Auguste, Amanda R Kahl, Brian M Gryzlak, Elizabeth A Chrischilles, Mary E Charlton, Sarah H Nash
PURPOSE: Evidence of the impact of the COVID-19 pandemic on cancer prevention and control is growing, but little is known about patient-level factors associated with delayed care. We analyzed data from a survey focused on Iowan cancer patients' COVID-19 experiences in the early part of the pandemic. METHODS: Participants were recruited from the University of Iowa Holden Comprehensive Cancer Center's Patients Enhancing Research Collaborations at Holden (PERCH) program...
April 2024: Cancer Medicine
Eli Marie Grindedal, Manuela Zucknick, Astrid Stormorken, Elin Rønne, Nora M Tandstad, William B Isaacs, Karol Axcrona, Lovise Mæhle
BACKGROUND: Pathogenic germline variants in the mismatch repair (MMR) genes are associated with an increased risk of prostate cancer (PCa). Since 2010 we have recommended MMR carriers annual PSA testing from the age of 40. Prospective studies of the outcome of long-term PSA screening are lacking. This study aimed to investigate the incidence and characteristics of PCa in Norwegian MMR carriers attending annual PSA screening (PSA threshold >3.0 ng/mL) to evaluate whether our recommendations should be continued...
April 17, 2024: Prostate
Zhiyu Zhang, Can Hu, Yuxin Lin, Ouyang Song, Dongkui Gong, Xuefeng Zhang, Nan Wang
OBJECTIVE: This study intends to examine the anticipatory power of clinical and radiological parameters in detecting clinically significant prostate cancer in patients demonstrating Prostate Imaging Reporting and Data System 3 lesions. METHODS: This was a retrospective study. The study included participation from 453 patients at the First Affiliated Hospital of Soochow University, sampled between September 2017 through August 2022. Each patient underwent a routine 12-core prostate biopsy followed by a 2 to 5 core fusion-targeted biopsy...
2024: Technology in Cancer Research & Treatment
Samaneh Rezaei, Mohammad Hasan Jafari Najaf Abadi, Mohammad Javad Bazyari, Amin Jalili, Reza Kazemi Oskuee, Seyed Hamid Aghaee-Bakhtiari
OBJECTIVES: MicroRNAs, which are micro-coordinators of gene expression, have been recently investigated as a potential treatment for cancer. The study used computational techniques to identify microRNAs that could target a set of genes simultaneously. Due to their multi-target-directed nature, microRNAs have the potential to impact multiple key pathways and their pathogenic cross-talk. MATERIALS AND METHODS: We identified microRNAs that target a prostate cancer-associated gene set using integrated bioinformatics analyses and experimental validation...
2024: Iranian Journal of Basic Medical Sciences
Fahad Alzahrani, Osama A Madkhali, Amani Khardali, Saad S Alqahtani, Abdulrahman M Hijri, Mazen A Alaqil, Yaseen A Madkhali, Zakaria Y Otayn, Nabeel Kashan Syed
BACKGROUND: Benign prostatic hyperplasia (BPH) is a prevalent condition in older men, causing significant morbidity. Despite recent progress, essential concerns of the disease remain under-researched. This study aims to assess knowledge and estimate self-reported prevalence of BPH in Saudi Arabian men. Understanding BPH prevalence in Saudi Arabia is essential for healthcare planning, resource allocation, public awareness, early detection, intervention, research, and addressing regional variations...
2024: Frontiers in Public Health
Jinyoung Moon, Elizabeth A Holzhausen, Yongseok Mun
INTRODUCTION: Night shift work could be a modifiable risk factor for prostate cancer. However, the epidemiological evidence is inconsistent. To summarize the existing evidence on this topic, we conducted a two-stage dose-response meta-analysis. METHODS: Medical librarians searched PubMed, EMBASE, and the Cochrane Library on December 30, 2022. Seven criteria were used to determine the inclusion of each study in the present analysis. RESULTS: Eleven cohort studies (12 cohort reports; total cases: 9366; and total person-years: 88,238,009) and seven case-control studies (seven case-control reports; total cases: 5593; and total controls: 6876) were included...
April 30, 2024: Heliyon
Wen Sheng, Bonan Li, Tiansong Sun, Congxu Zhu, Yingqiu Li, Wenjing Xu
Ferroptosis is a form of regulatory cell death that relies on iron and reactive oxygen species (ROS) to inhibit tumors. The present study aimed to investigate whether icariin-curcumol could be a novel ferroptosis inducer in tumor inhibition. Various concentrations of icariin-curcumol were used to stimulate prostate cell lines (RWPE-2, PC-3, VCAP and DU145). Small interfering negative control (si-NC) and si-nuclear factor erythroid 2-related factor 2 (Nrf2) were used to transfect DU145 cells. Cell viability was determined by using cell counting kit-8...
May 2024: Experimental and Therapeutic Medicine
Lubna F Abu-Niaaj, Hala I Al-Daghistani, Ibrahim Katampe, Bashaer Abu-Irmaileh, Yasser K Bustanji
This is a comparative study to evaluate the effectiveness of six pomegranate peel extracts (PPEs) as antibacterial and antiproliferative agents. The Six PPEs were prepared using four solvent systems and each filtrate was concentrated to a gummy material to be used in the evaluation. The well-diffusion method was used to evaluate their antimicrobial activity against bacteria typically associated with food spoilage: Escherichia coli , Pseudomonas aeruginosa , Salmonella typhimurium , Listeria monocytogenes , Staphylococcus epidermidis , Staphylococcus aureus , and three Bacillus species ...
April 2024: Food Science & Nutrition
Edmund Chiong, Declan G Murphy, Nicholas Buchan, Kenneth Chen, Sarah S Chen, Melvin L K Chua, Agus Rizal Hamid, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallik, Chee Fai Ng, Teng Aik Ong, Darren M C Poon, Yeong-Shiau Pu, Marniza Saad, Kathryn Schubach, Kiyoshi Takahara, Jeremy Tey, Sue-Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Scott Williams, Dingwei Ye, Ian D Davis
AIM: The aim of the third Asia-Pacific Advanced Prostate Cancer Consensus Conference (APAC APCCC 2023) was to discuss the application in the Asia-Pacific (APAC) region of consensus statements from the 4th Advanced Prostate Cancer Consensus Conference (APCCC 2022). METHODS: The one-day meeting in July 2023 brought together 27 experts from 14 APAC countries. The meeting covered five topics: (1) Intermediate- and high-risk and locally advanced prostate cancer; (2) Management of newly diagnosed metastatic hormone-sensitive prostate cancer; (3) Management of non-metastatic castration-resistant prostate cancer; (4) Homologous recombination repair mutation testing; (5) Management of metastatic castration-resistant prostate cancer...
April 16, 2024: Asia-Pacific Journal of Clinical Oncology
Selcen Ari Yuka, Alper Yilmaz
Competing endogenous RNAs play key roles in cellular molecular mechanisms through cross-talk in post-transcriptional interactions. Studies on ceRNA cross-talk, which is particularly dependent on the abundance of free transcripts, generally involve large- and small-scale studies involving the integration of transcriptomic data from tissues and correlation analyses. This abundance-dependent nature of ceRNA interactions suggests that tissue- and condition-specific ceRNA dynamics may fluctuate. However, there are no comprehensive studies investigating the ceRNA interactions in normal tissue, ceRNAs that are lost and/or appear in cancerous tissues or their interactions...
April 17, 2024: BioData Mining
Tina Nayerpour Dizaj, Abolfazl Doustmihan, Behnaz Sadeghzadeh Oskouei, Morteza Akbari, Mehdi Jaymand, MirAhmad Mazloomi, Rana Jahanban-Esfahlan
One of the contributing factors in the diagnosis and treatment of most cancers is the identification of their surface antigens. Cancer tissues or cells have their specific antigens. Some antigens that are present in many cancers elicit different functions. One of these antigens is the prostate stem cell antigen (PSCA) antigen, which was first identified in the prostate. PSCA is a cell surface protein that has different functions in different tissues. It can play an inhibitory role in cell proliferation as well as a tumor-inducing role...
April 16, 2024: Cancer Cell International
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.